Biognosys raises USD 5 million
Biognosys raised USD 5 million in an extended series C financing round and secured new investors. Biognosys, which specialises in proteomics, develops methods for researching proteomes, or the entire complement of proteins in an entity such as a cell. This provides the foundation for developing innovative treatments.
The company will use the new funds to accelerate the development of next generation proteomics workflows and products for high-content and high-throughput protein analysis, according to a statement. It also plans to extend its commercial operations.
"The feedback that we get from our customers shows there is a shift in the perception of proteomics, away from a highly specialized analytical tool and towards a universally applicable technology for mode of action studies and biomarker development,” commented Oliver Rinner, CEO and co-founder of Biognosys.
According to Rinner, the new funds will help Biognosys to further extend its technological lead, to accelerate the development of new products and to better address the life science research market outside the classical proteomics field.